COP vs PFE: Which Is the Better Buy?
Side-by-side comparison of ConocoPhillips and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
ConocoPhillips · Energy
$125.78
-2.1% upside to fair value
Grade C
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
COP |
PFE |
| Current Price |
$125.78 |
$26.33 |
| Fair Value Estimate |
$123.15 |
$33.85 |
| Upside to Fair Value |
-2.1%
|
+28.6%
|
| Market Cap |
$153.3B |
$149.8B |
| Forward P/E |
21.0x
|
19.3x
|
| EV / EBITDA |
7.5x
|
12.9x
|
| Price / Sales |
2.6x
|
2.4x
|
| Price / FCF |
8.4x
|
16.5x
|
| Revenue Growth YoY |
-2.5%
|
-1.2%
|
| Gross Margin |
33.1%
|
70.3%
|
| Operating Margin |
25.4%
|
24.7%
|
| Return on Equity |
11.3%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
11.96%
|
6.06%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
ConocoPhillips is a leading independent oil and gas exploration and production company with a strong focus on low-cost shale assets and sustainability initiatives. The company benefits from a durable competitive position due to its cost advantage and early ESG leadership, but faces near-term earnings pressure as revenue declined 2.5% and earnings fell 23.4% in the most recent quarter year-over-ye…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
COP |
PFE |
| Zone Low |
$92.36 |
$25.39 |
| Zone High |
$104.68 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|